A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Eleclazine (Primary)
  • Indications Ventricular arrhythmias
  • Focus Therapeutic Use
  • Acronyms TEMPO
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 15 Nov 2017 Primary endpoint (Overall occurrence (total number) of appropriate ICD interventions (ATP or shock) through Week 24) has not been met as per the results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 03 Nov 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top